2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 ☆
Parsons H, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson V, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina T, Carey L, Rimawi M, Miller K, Stearns V, Specht J, Falkson C, Burstein H, Wolff A, Winer E, Tayob N, Krop I, Makrigiorgos G, Golub T, Mayer E, Adalsteinsson V. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 ☆. Annals Of Oncology 2023, 34: 899-906. PMID: 37597579, PMCID: PMC10898256, DOI: 10.1016/j.annonc.2023.08.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerResidual cancer burdenNeoadjuvant chemotherapyCancer burdenBreast cancerWeek 3Additional neoadjuvant chemotherapyPlasma samplesCase-control analysisCtDNA clearanceCtDNA positivityNeoadjuvant paclitaxelDisease recurrenceProspective studyWeek 12RCB 0CtDNA assaysPatientsSufficient tissueChemotherapyTumor fractionTumor DNARCB-3RespondersAdditional studies
2008
Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)
Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, Diamandis EP, Dimopoulos MA. Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Science 2008, 99: 2224-2229. PMID: 18957059, PMCID: PMC11159123, DOI: 10.1111/j.1349-7006.2008.00942.x.Peer-Reviewed Original ResearchConceptsOvarian cancerOverall survivalPrognostic valueKLK6 expressionSurvival analysisPlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerAdvanced ovarian cancerProgression-free survivalProtein expressionStage ovarian cancerInferior patient outcomesUnivariate survival analysisMultivariate survival analysisImportant prognostic biomarkerSerine protease enzyme familyExpression levelsProtein expression levelsSurgical debulkingCombination chemotherapyPatient outcomesPrognostic biomarkerPrognostic variablesSufficient tissueTherapeutic target
2006
Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with β-catenin levels and outcome in patients with epithelial ovarian cancer
Bamias A, Yu Z, Weinberger P, Markakis S, Kowalski D, Camp R, Rimm D, Dimopoulos M, Psyrri A. Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with β-catenin levels and outcome in patients with epithelial ovarian cancer. Annals Of Oncology 2006, 17: 1797-1802. PMID: 16971669, DOI: 10.1093/annonc/mdl310.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerPatient outcomesDCC expressionPlatinum-paclitaxel combination chemotherapyProgression-free survival ratesAdvanced stage ovarian cancerOvarian cancer tissue microarrayAssociation of DCCCancer tissue microarrayPoor patient outcomesBeta-catenin levelsDCC tumor suppressor geneColorectal cancer (DCC) proteinMedian followSurgical debulkingCombination chemotherapyPrognostic significanceEntire cohortPreclinical dataClinicopathological parametersAntitumor functionΒ-catenin levelsTissue microarraySufficient tissue
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply